Obsessive-compulsive disorder evaluation

Agor, agoraphobia Dep, depression Dx, diagnosis MDD, major depressive disorder OCD, obsessive-compulsive disorder Not eval, not evaluated. 

Bher P, Bergeron R, Hebert C Differential effectiveness of pindolol addition in treatment-resistant obsessive-compulsive disorder and depression. Poster No. 7, New Chnical Drug Evaluation Unit (NCDEU) Program, 35th Annual Meeting, Orlando, FL, May 31-June 3, 1995... 

Goodman WK, Price LH, Delgado PL, et al Specificity of serotonin reuptake inhibitors in the treatment of obsessive compulsive disorder comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 47 577-585, 1990b Goodman WK, Rasmussen SA, Foa EB, et al Obsessive compulsive disorder, in Clinical Evaluation of Psychotropic Drugs Principles and Guidance. Edited by Prien RF, Robinson DS. New York, Raven, 1994, pp 431-466 Goodnick P Effects of lithium on indices of 5HT and catecholamines in the clinical content a review. Lithium 1 65-73, 1990... 

The aims of a prospective study in 113 consecutively hospitalized young patients (mean age 22 years) were to determine whether the severity of obsessive-compulsive symptoms differs during treatment with olanzapine or risperidone and to establish whether the duration of neuroleptic treatment is related to the severity of obsessive-compulsive symptoms (152). At baseline and week 6 assessments, obsessive-compulsive symptoms were found in 32 of 106 evaluable cases and 16 met DSM-IV criteria for obsessive-compulsive disorder, but there were no differences in patients taking olanzapine or risperidone. However, the severity of obsessive-compulsive symptoms was associated with the duration of treatment with olanzapine. 

There have been reports that selective serotonin reuptake inhibitors, which inhibit CYP1A2, increase plasma olanzapine concentrations (SEDA-24, 71 SEDA-26, 63). In a recent open add-on trial, 21 patients with obsessive-compulsive disorder unresponsive to treatment with paroxetine 60 mg/day for at least 12 weeks, took additional olanzapine 10 mg/day (280). Steady-state plasma concentrations of paroxetine were not changed, and 7 patients were rated as responders at final evaluation. Sedation (n = 12), weight gain up to 3 kg (n = 8), dry mouth (n = 6), and constipation (n = 3) were the most frequent adverse effects. 

Bos, M., Jenck, E., Martin, J. R., Moreau, J.-L., Sleight, A. J., Wichmann, J., Widmer, U. Novel agonists of 5HT2C receptors. Synthesis and biological evaluation of substituted 2-(indol-l-yl)-l-methylethylamines and 2-(indeno[l,2-h]pyrrol-l-yl)-l-methylethyl-amines. Improved therapeutics for obsessive compulsive disorder. 7. Med. Chem. 1997,40,2762-2769. 

Shapiro AK, Shapiro E. Evaluation of the reported association of obsessive compulsive symptoms or disorders with Tourette s disorder. Compr Psychiatry 1992 23 152-165. 

---